课题基金 / 基金详情

Identification of Muscle-Specific Biomarkers of Fatty Acid beta-Oxidation

Identification of Muscle-Specific Biomarkers of Fatty Acid beta-Oxidation
脂肪酸β-氧化的肌肉特异性生物标志物的鉴定
批准号:
8308909
负责人:
Sean Harrison Adams
金额:
$22.16万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2015-06-30

项目摘要

项目成果

Sean Harrison Adams的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Elevated fat levels within skeletal muscle cells (intramyocellular lipids) are highly correlated with muscle and whole-body insulin resistance, and more prevalent in obesity. The molecular links and metabolic shifts driving this association remain open to debate, but notably, reduced muscle mitochondrial fatty acid (FA) beta-oxidation is more prevalent among insulin-resistant/diabetic persons. Therefore, discovery of biomarkers reflective of the status of an individual's muscle FA beta-oxidation activity or capacity would have tremendous prognostic and diagnostic value in terms of diabetes. Furthermore, characterization of metabolites associated with muscle mitochondrial fat metabolism should uncover candidate signaling factors which tie FA beta-oxidation to insulin signaling. We propose to identify, for the first time, specific biomarkers of muscle FA beta- oxidation using multiple metabolomic analytical platforms to compare metabolite profiles in samples derived from biological systems displaying disparate muscle fat combustion, including: isolated mitochondrial organelles and muscle cells catabolizing FA at different rates, a UCP3 transgenic animal model, and human subjects harboring a UCP3 truncation polymorphism (Aims 1 & 2). Pilot validation studies in Aim 3 will test whether plasma metabolites and/or metabolite signatures that track muscular FA beta-oxidation (as identified in Aims 1 and 2) can be experimentally increased in obese, insulin-resistant subjects via a diet-exercise regimen designed to improve muscle fitness and FA combustion. Aim 1--Identify Metabolite Biomarkers of Muscle Fat Combustion in Organelle, Cell, and Animal Models Displaying Significantly Altered Fatty Acid beta-Oxidation. We will determine how metabolite profiles shift in models displaying increased muscle beta-oxidation (uncoupling protein 3-overexpressing muscle cell line and muscle UCP3-transgenic mice), and hypothesize that profiles in UCP3-overexpressing systems will reflect increased FA beta-oxidation. Complementary studies will identify tissue-specific metabolites generated by mitochondria in the course of palmitate catabolism in vitro, comparing muscle to liver and kidney preparations. Aim 2--Identify Metabolite Biomarkers of Muscle Fat Combustion in Humans Harboring a UCP3 Missense Polymorphic Allele. We predict that subjects with this polymorphism (which yields a truncated UCP3 and 50% decreased whole-body fat combustion) will display a distinctive plasma metabolite profile indicative of reduced muscle FA oxidation, when compared to subjects without the polymorphism. Aim 3--Determine Whether Metabolomic Profiles Reflective of Muscle Fat Combustion Predict Metabolic Health Changes Following Diet & Exercise Intervention in Obese Subjects. We hypothesize that biomarkers reflective of normal to increased muscle beta-oxidation will be increased, and markers indicative of poor muscle fat combustion reduced, in a cohort of sedentary obese subjects undergoing a 4 month diet- exercise protocol which will increase muscle fitness and improve insulin action. PUBLIC HEALTH RELEVANCE: A reduced ability of the pancreatic hormone insulin to trigger tissue uptake of blood sugar is an early event in the course of development of type 2 diabetes mellitus (T2DM), and the muscle beds are important sites for this phenomenon in many people. Relatively poor fat combustion by fasting muscle is often correlated with insulin resistance, even in the pre-diabetic state. Thus, the overarching aim of our research-- identification of clinically-relevant biomarkers of muscle fat metabolism--is critical to help identify at-risk persons, determine etiology of disease, and ultimately thwart development of T2DM through nutritional, physical activity, and pharmacological interventions.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.metabol.2014.02.009
发表时间: 2014-05
期刊: Metabolism: clinical and experimental
影响因子: --
作者: [Hirahatake KM, Slavin JL, Maki KC, Adams SH]
通讯作者: Adams SH
DOI: 10.1152/ajpendo.00156.2018
发表时间: 2019-01
期刊: American journal of physiology. Endocrinology and metabolism
影响因子: --
作者: [Jie Zhang;S. Bhattacharyya;R. Hickner;A. Light;Christopher J. Lambert;B. Gale;O. Fiehn;S. Adams]
通讯作者: Jie Zhang;S. Bhattacharyya;R. Hickner;A. Light;Christopher J. Lambert;B. Gale;O. Fiehn;S. Adams
DOI: 10.1038/nrendo.2015.129
发表时间: 2015-10
期刊: Nature reviews. Endocrinology
影响因子: --
作者: [McCoin CS, Knotts TA, Adams SH]
通讯作者: Adams SH
Decreased expression of adipose CD36 and FATP1 are associated with increased plasma non-esterified fatty acids during prolonged fasting in northern elephant seal pups (Mirounga angustirostris).
北象海豹幼崽 (Mirounga angustirostris) 长期禁食期间,脂肪 CD36 和 FATP1 表达的减少与血浆非酯化脂肪酸增加有关。
DOI: 10.1242/jeb.069070
发表时间: 2012
期刊: The Journal of experimental biology
影响因子: --
作者: [Viscarra,JoseAbraham, Vázquez-Medina,JoséPablo, Rodriguez,Ruben, Champagne,CoryD, Adams,SeanH, Crocker,DanielE, Ortiz,RudyM]
通讯作者: Ortiz,RudyM
9
    Metabolism and Metabolic Health Core
    • 批准号:
      10588974
    • 项目类别:
    • 资助金额:
      $18.27万
    • 财政年份:
      2023
    • 负责人:
      Sean Harrison Adams
    • 依托单位:
    California Partnership for Personalized Nutrition
    • 批准号:
      10669429
    • 项目类别:
    • 资助金额:
      $100.0万
    • 财政年份:
      2022
    • 负责人:
      Sean Harrison Adams
    • 依托单位:
    California Partnership for Personalized Nutrition
    • 批准号:
      10386527
    • 项目类别:
    • 资助金额:
      $108.85万
    • 财政年份:
      2021
    • 负责人:
      Sean Harrison Adams
    • 依托单位:
    California Partnership for Personalized Nutrition
    • 批准号:
      10540243
    • 项目类别:
    • 资助金额:
      $291.19万
    • 财政年份:
      2021
    • 负责人:
      Sean Harrison Adams
    • 依托单位:
    海外基金